Document is current
Any future updates will be listed below
-
Authors
Noda, Kaoru
Kato, Takehiro https://orcid.org/0000-0003-3236-2463
Nomura, Nao
Sakai, Mayu
Kubota, Sodai
Hirose, Tokuyuki
Liu, Yanyan
Takahashi, Yoshihiro
Takao, Ken
Mizuno, Masami
Hirota, Takuo
Suwa, Tetsuya
Horikawa, Yukio
Yabe, Daisuke
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (26111004, 20K19673)
young researchers from Japan Association for Diabetes Education and Care
- License Information
-
More Information
Article History
Received: 14 February 2022
Accepted: 22 May 2022
First Online: 15 June 2022
Declarations
:
: DY has received consulting/lecture fees from Eli Lilly Japan K.K., Novo Nordisk Pharma Ltd., Ono Pharmaceutical Co. Ltd., and Takeda Pharmaceutical Company Limited. DY also received grants from Arkray Inc., Novo Nordisk Pharma Ltd., Nippon Boehringer Ingelheim, Ono Pharmaceutical Co. Ltd., Taisho Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, and Terumo Corporation. YH received lecture fees from Kowa and MSD. KN, TK, NN, MS, SK, TH, YL, YT, KT, MM, TH, KI and TS declare that they have no conflict of interest. All authors declare that they have no competing interests relevant to this study.
: Formal ethics approval was waived for this paper by the ethics committee of Gifu University Graduate School of Medicine due to its being a case report.
: All procedures performed in studies involving human participants followed the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from the patient.
: All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
